News
India Has 10,500+ Pharma Manufacturing Facilities and the Most USFDA-Compliant Plants Outside the US — What India Pharma 2026 Revealed About Our Real Strengths
By Mustafa Shariff, Editor in Chief · April 17 , 2026 · 5 min read
Summary
- India Pharma 2026 Key Outcomes: From ₹3,591 Crore API Import Substitution to the $75B Biosimilar Opportunity
- India Pharma 2026 concluded with clear strategic outputs. Here is a comprehensive summary of the key outcomes, data points, and policy signals from the conference.
The 9th edition of India Pharma 2026 concluded on April 14 having delivered a two-day agenda of strategic clarity about where India's pharmaceutical sector is heading and what obstacles stand in the way. The conference brought together the DCGI, the US FDA Country Director, state health ministers, and CEOs from Sun Pharma, Cipla, Zydus, Eli Lilly, Abbott, and Mankind Pharma alongside policy officials from the Department of Pharmaceuticals and the Ministry of Health. The key outputs from the conference merit detailed examination.
The Baseline: India's Pharmaceutical Strengths
Arjun Juneja, COO of Mankind Pharma and Chair of the FICCI Pharma Committee, presented the baseline numbers that India's pharma ambition is built on. More than 3,000 pharma companies. Over 10,500 manufacturing facilities. The highest number of USFDA-compliant manufacturing plants outside the United States. Pharmaceutical exports of $30.5 billion to 191 countries. These are extraordinary numbers — and they represent the foundation on which India's innovation ambition is being built.
Juneja's implicit point — and the conference's animating tension — is that these manufacturing numbers have not translated into proportionate innovation output. India builds medicines that others have discovered. The India Pharma 2026 agenda is explicitly about closing that gap.
PLI Scheme Impact: ₹3,591 Crore in API Import Substitution
One of the most concrete data points from the conference was the PLI (Production-Linked Incentive) scheme performance. PLI schemes for pharmaceuticals and bulk drugs have already resulted in the substitution of ₹3,591 crore in API, KSM, and drug intermediate imports — meaning Indian manufacturers have built domestic production capacity to replace that value of previously imported raw materials. Total investment under the PLI scheme stands at ₹40,890 crore against a target of ₹17,274.96 crore, and total sales have reached ₹3,16,797 crore as of September 2025.
This API import substitution is strategically critical for a specific reason: India currently imports approximately 70% of its API requirements from China. The PLI scheme is the primary mechanism for reducing this dependence, and the ₹3,591 crore substitution achievement — while meaningful — needs to be dramatically accelerated if India is to achieve genuine supply chain resilience.
CDSCO Reform: Making India Faster for Drug Approval
Multiple speakers at India Pharma 2026 called for CDSCO — India's drug regulatory authority — to be reformed to reduce approval timelines for both domestically developed molecules and innovative therapies developed abroad. India currently faces a significant regulatory time gap: drugs approved by the US FDA and EMA often take years longer to receive CDSCO approval, meaning Indian patients wait for access to innovations that patients in other markets have already been receiving for years.
Punya Salila Srivastava, Secretary of the Ministry of Health, reiterated the government's commitment to streamlining approval processes — specifically noting measures aimed at reducing review timelines and improving the ease of conducting clinical research in India. The Biopharma SHAKTI scheme's plan to strengthen CDSCO through a dedicated scientific review cadre is the structural response to this challenge.
The $75 Billion Biosimilar Signal
The conference's most commercially significant data point was MoS Anupriya Patel's citation of the global biosimilars market reaching $75 billion by 2030. India's biosimilar manufacturers — Biocon, Dr Reddy's, Intas, Cipla — have demonstrated the capability to develop, manufacture, and export biosimilars to regulated markets. The conference framed the $75 billion number as India's next major pharmaceutical export opportunity, with Biopharma SHAKTI's ₹10,000 crore investment designed to build the regulatory and clinical infrastructure to capture a meaningful share.
BHC Perspective
At Bengaluru Health Community, India Pharma 2026 has served its purpose: it has made India's pharmaceutical policy agenda concrete, time-bound, and accountable. The CDSCO reform commitment, the clinical trial site network target, the biosimilar market opportunity — these are now public commitments that the industry and media will track. For founders building in the pharma innovation ecosystem, the conference has created a clarity of direction that makes investment and product development decisions easier.
Frequently Asked Questions
Q: What are India's key pharma manufacturing statistics?
A: India has over 3,000 pharma companies and more than 10,500 manufacturing facilities — including the highest number of USFDA-compliant plants outside the US — exporting $30.5 billion annually to 191 countries.
Q: What has the PLI scheme achieved for Indian pharma?
A: PLI schemes have substituted ₹3,591 crore in API and drug intermediate imports with domestic production, with total investment reaching ₹40,890 crore against a target of ₹17,274 crore, and total scheme sales of ₹3,16,797 crore as of September 2025.
Q: What is the biosimilar market opportunity for India?
A: The global biosimilars market is projected to reach $75 billion by 2030. India's biosimilar manufacturers including Biocon, Dr Reddy's, Intas, and Cipla are already active in this space, and Biopharma SHAKTI's ₹10,000 crore investment is designed to build infrastructure for significantly expanded market share.